Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
STAMFORD, Conn., Oct. 17, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at ANESTHESIOLOGY® 2017, the American Society of Anesthesiologists’ annual meeting, to be held October 21-25, 2017 in Boston.
Presentations will include clinical trial data for CR845, Cara’s first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
Details for the presentations are as follows:
| CR845 Oral Abstract Presentation: | |
| Title: | "Respiratory Effects of I.V. CR845: A Peripherally Acting, Selective Kappa Opioid Receptor Agonist” |
| Abstract Number: | JS01 |
| Date / Time: | Sunday, October 22, 2017; 9:00 a.m. – 12:00 p.m. ET |
| Presenter: | Eugene Viscusi, M.D., Director, Acute Pain Management, Thomas Jefferson University |
| Satellite Symposium: | |
| Title: | "A Potential New Path to Pain Relief: Multimodal Analgesia for Enhanced Recovery with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)” |
| Date / Time: | Sunday, October 22, 2017; 7:00 – 8:00 a.m. ET |
| Presenters: | Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics |
| Christopher L. Wu, M.D., Professor, Division of Obstetric Anesthesiology, Division of Regional Anesthesia and Acute Pain Medicine, Department of Anesthesiology, The Johns Hopkins Hospital | |
For information about ANESTHESIOLOGY® 2017, visit www.asahq.org/annualmeeting.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]
